PMV Pharmaceuticals Inc
For the period ended Jun 30, 2024. Filed Aug 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 8, 2024
PMVP$1.22-2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (Unaudited)
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(16,483) | $(36,564) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 5,377 | 6,085 |
| Depreciation | 734 | 540 |
| Accretion of discounts on marketable securities | (3,004) | (1,669) |
| Non-cash lease income | (193) | (188) |
| Other, net | 7 | — |
| Change in operating assets and liabilities: | ||
| Prepaid expenses and other assets | (1,518) | 2,758 |
| Operating lease right-of-use assets and liabilities | 241 | — |
| Accounts payable | 1,296 | 493 |
| Accrued expenses | (4,239) | 632 |
| Net cash used in operating activities | (17,782) | (27,913) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (598) | (721) |
| Purchases of marketable securities | (71,374) | (129,552) |
| Maturities of marketable securities | 100,461 | 115,955 |
| Net cash provided (used) by investing activities | 28,489 | (14,318) |
| Cash flows from financing activities: | ||
| Issuance of common stock, net of issuance costs | — | 2,026 |
| Proceeds from the exercise of stock options and common stock issued under the 2020 EIP | 141 | 117 |
| Net cash provided by financing activities | 141 | 2,143 |
| Impact of exchange rates on cash, cash equivalents, and restricted cash | (28) | — |
| Net increase (decrease) in cash and cash equivalents | 10,820 | (40,088) |
| Cash, cash equivalents, and restricted cash | ||
| Cash, cash equivalents, and restricted cash - beginning of period | 38,528 | 109,119 |
| Cash, cash equivalents, and restricted cash - end of period | $49,348 | $69,031 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.